Akira Nishimura

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori</i> eradication: a phase III, randomised, double-blind study

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino et al. · Gut · 2016 · 420 citations · Full text

Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Yuichi Sakurai, Yujiro Mori, Hiroyuki Okamoto et al. · Alimentary Pharmacology & Therapeutics · 2015 · 369 citations · Full text

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of <scp>TAK</scp>‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

Helen Jenkins, Yuichi Sakurai, Akira Nishimura et al. · Alimentary Pharmacology & Therapeutics · 2015 · 294 citations · Full text

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

Kiyoshi Ashida, Yuichi Sakurai, Tetsuharu Hori et al. · Alimentary Pharmacology & Therapeutics · 2015 · 291 citations · Full text

Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy.

Toshihito Seki, Masayuki Wakabayashi, Taiichi Nakagawa et al. · PubMed · 1999 · 216 citations